SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today reported positive preliminary data from a cohort of 45 patients with metastatic breast cancer (MBC) participating in the ongoing cabozantinib phase 2 randomized discontinuation trial (RDT). Sara Tolaney, M.D., M.P.H., Instructor in the Department of Medicine at Harvard Medical School and an Attending Physician, Medical Oncology, at Dana-Farber Cancer Institute, presented the data today in a poster session at the San Antonio Breast Cancer Symposium (Abstract #850463; Poster P1-17-10).
